BioNTech Results Presentation Deck

Clinical Program to Assess Safety, Tolerability and Immunogenicity of an Omicron-Adapted Vaccine Evaluating different Omicron monovalent vaccine regimens N-1500, 18-55 years and >55 years Vaccine experienced and naïve subjects 1 ● 16 Omicron-based vaccine to to - to toto 3rd dose or 3rd+4th dose BNT162b2 ● ● 2 BNT162b2 4th dose to to to Omicron-based vaccine Evaluating bivalent and combination of Omicron-based vaccine and BNT162b2 N-650, >55 years Two dosages: 30 ug and 60 µg mml=0 30 mg or 60 mg 3 3-dose primary regimen 1 BioNTech. Available at: https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-initiate-study-evaluate-omicron-based-covid. Accessed January 2022; 2 Clinical Trials.gov. Available at: https://www.clinical trials.gov/ct2/show/NCT04955626. Accessed March 2022. Omicron-based vaccine to toto Vaccine naïve subjects BIONTECH

View entire presentation